July 14, 2008 - Pfizer, Inc announced that it will present nine abstracts from its Alzheimer’s disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) in Chicago, July 26-31......Data from Pfizer to be presented at the meeting include:
Receptor for Advanced Glycation End-products (RAGE) Antagonist:
Pfizer is in collaboration with TransTech Pharma to develop and commercialize a portfolio of RAGE modulators. RAGE is a cell-surface receptor that may play a key role in multiple aspects of AD. Targeting RAGE for Alzheimer's is a novel approach and Pfizer is pioneering this approach in the clinic.
- Initial Phase II data on the safety and tolerability of Pfizer's oral RAGE antagonist known as PF-04494700...
- Preclinical data on the effect of PF-04494700 on chronic inflammation and buildup of amyloid plaques - two abnormal processes that are implicated in causing damage and death to brain cells in AD...
Humanized Anti-Amyloid Monoclonal Antibody: Preclinical data on the effect of PF-04360365, Pfizer's investigational monoclonal antibody in Phase 1 trials, on beta amyloid levels in the brains of mice...
Additional Preclinical Research: Pfizer will also present data on a potential blood biomarker that could help in identifying patients with AD; two studies on the role of the brain’s immune system in the formation of amyloid plaques; a potential method of using novel imaging and microscopic analysis to quantify AD neuropathology, and early research on an additional investigational Pfizer compound on the inhibition of an enzyme in the brain... Pfizer's Press Release -
